课题基金 / 基金详情

Immunotherapy of leukemias by targeting hematopoietic lineage-specific minor histocompatibility antigens

Immunotherapy of leukemias by targeting hematopoietic lineage-specific minor histocompatibility antigens
通过靶向造血谱系特异性次要组织相容性抗原进行白血病免疫治疗
批准号:
13671092
负责人:
AKATSUKA Yoshiki
金额:
$2.18万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002

项目摘要

项目成果

AKATSUKA Yoshiki的其他基金

相似基金

相关文献

中文摘要
翻译
细胞毒性T淋巴细胞(CTL)对次要组织相容性抗原(mHAgs)具有特异性,其组织表达仅限于造血细胞,可用于同种异体造血细胞移植(HCT)后复发白血病的免疫治疗。我们在研究期间获得了26例接受HCT的患者的外周血样本,并试图产生受HLA- a24(日本最常见的HLA)限制的CTL。为了方便操作,我们设计了一种新的方法,通过使用HLA转染的B淋巴母细胞样细胞系逆转录病毒和基于干扰素γ释放的检测来筛选CTL系中受HLA感兴趣的mhags特异性CTL的存在。我们成功地生成了4个不同的hla - a24限制性CTL克隆。利用遗传标记分型的CEPH大家族成员的LCL,结合连锁分析,编码mHAgs的2个受HLA-A24和B44限制的不同CTL的基因位于15q24.5染色体上。在该区域内的39个基因中,我们使用各种在线数据库(dbSNP, SAGE, UCSC Human Genome Browser)和软件(BIMAS)确定了编码mHAgs的基因。BCL2A1基因具有三个单核苷酸多态性,其中两个编码两个mHAgs表位,通过使用的2个CTL克隆检测到。BCL2A1仅在造血细胞中表达,因此被认为是白血病免疫治疗的良好候选者。我们已经成功地使用肽脉冲抗原提呈细胞诱导了BCL2A1 mHAg特异性CTL系。我们计划开展一项I期临床研究,使用体外扩增的BCL2A1 mHAgs特异性CTL克隆,对异体HCT后复发白血病患者进行过继免疫治疗。
英文摘要
Cytotoxic T lymphocytes (CTL) specific for minor histocompatibility antigens (mHAgs) whose tissue expression is limited to hematopoietic cells are useful for immunotherapy of relapsed leukemia following allogeneic hematopoietic cell transplantation (HCT). We have obtained peripheral blood samples from 26 patients receiving HCT during the research period and attempted to generate CTL restricted by HLA-A24, the most common HLA in Japanese. To facilitate the procedure, we devised a novel method to screen for the presence of mHAgs-specific CTL restricted by HLA of interest in CTL lines by using HLA transfected B lymphoblastoid cell lines retrovirally and interferon-gamma release-based assays. We successfully generated 4 distinct HLA-A24-restricted CTL clones. By using LCL from members of large CEPH families whose genetic markers had been typed in combination with linkage analysis, gene(s) encoding mHAgs detectable 2 distinct CTL restricted by HLA-A24 and B44 were located at chromosome 15q24.5. Of 39 genes within the region, we determined the gene encoding the mHAgs using various online databases (dbSNP, SAGE, UCSC Human Genome Browser) and softwares (BIMAS). The gene, BCL2A1, possesses three single nucleotide polymorphisms, two of which turned out to encode two mHAgs epitopes detected by the 2 CTL clones used. BCL2A1 is expressed in only hematopoietic cells, thus is thought to be a good candidate for immunotherapy of leukemia. We have successfully induced CTL lines specific for the BCL2A1 mHAg using peptide-pulsed antigen presenting cells. We plan on conducting a phase I clinical study of adoptive immunotherapy for patients with relapsed leukemia following allogeneic HCT using ex vivo expanded CTL clones specific for the BCL2A1 mHAgs.
期刊论文(17)
专著(0)
科研奖励(0)
会议论文
Yoshiki Akatsuka: "Minor histocompatibility antigens and their clinical significance"Saishin Igaku. 56. 186-191 (2001)
Yoshiki Akatsuka:“次要组织相容性抗原及其临床意义”Saishin Igaku。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yoshiki Akatsuka: "Targeted cloning of cytotoxic T cells specific for minor histocompatibility antigens restricted by HLA class I molecules of interest"Transplantation. 74. 1773-1780 (2002)
Yoshiki Akatsuka:“针对受 HLA I 类感兴趣分子限制的次要组织相容性抗原进行特异性细胞毒性 T 细胞的靶向克隆”。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Mikinori Miyazaki: "Potential limitations in using minor histocompatibility antigen-specific cytotoxic T cells for targeting solid tumor cells"Clinical Immunology. (in press).
Mikinori Miyazaki:“使用次要组织相容性抗原特异性细胞毒性 T 细胞靶向实体瘤细胞的潜在局限性”临床免疫学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yoshiki Akatsuka: "Efficient cloning and expression of HLA class I cDNA in human B-lymphoblastoid cell lines"Tissue Antigens. 59. 502-511 (2002)
Yoshiki Akatsuka:“在人 B 类淋巴母细胞系中有效克隆和表达 HLA I 类 cDNA”组织抗原。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 11 条
    Development of novel identification methods of SNPs responsible for minor H antigens and open public internet software tool
    • 批准号:
      21591256
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2009
    • 负责人:
      AKATSUKA Yoshiki
    • 依托单位:
    Development of immunotherapy targeting minor antigens
    • 批准号:
      17016089
    • 项目类别:
      Grant-in-Aid for Scientific Research on Priority Areas
    • 资助金额:
      $34.82万
    • 财政年份:
      2005
    • 负责人:
      AKATSUKA Yoshiki
    • 依托单位:
    Identification of minor histocompatibility antigens as targets for allogeneic adoptive immunotherapy against hematological malignancies.
    • 批准号:
      17591025
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.18万
    • 财政年份:
      2005
    • 负责人:
      AKATSUKA Yoshiki
    • 依托单位:
    Identification of minor histocompatibility antigens restricted by HLA alleles common in Japanese
    • 批准号:
      15591035
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.18万
    • 财政年份:
      2003
    • 负责人:
      AKATSUKA Yoshiki
    • 依托单位:
    海外基金